Side effects of proton pump inhibitors: how real are they in clinical practice?
https://doi.org/10.30629/0023-2149-2024-102-1-57-61
Abstract
The presented article discusses the risk of side eff ects when using proton pump inhibitors (PPI): infectious complications (small intestinal bacterial overgrowth, Clostridium difficile-associated disease, community-acquired pneumonia, spontaneous bacterial peritonitis), stomach cancer, myocardial infarction, hypomagnesemia, iron and vitamin B12 deficiency, kidney damage, bone fractures, dementia, Alzheimer’s disease. An analysis of the literature indicates a weak causal relationship between the occurrence of these diseases and the use of PPI. Nevertheless, it is necessary to strive for the appointment of these drugs in the minimum effective dose and for as short a time as possible.
About the Authors
A. A. Sheptulin
I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russia (Sechenov University)
Russian Federation
Russian Federation
Arkadiy A. Sheptulin — Doctor of Medical Sciences, Professor, Professor of the Department of Propaedeutics of Internal Diseases, Gastroenterology and Hepatology of the Institute of Clinical Medicine named after N.V. Sklifosovsky
Moscow
A. A. Kirilovsky
Family Doctor
Russian Federation
Russian Federation
Aleksey A. Kirilovsky — physician
Moscow
K. S. Kirilovskaya
I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russia (Sechenov University)
Russian Federation
Russian Federation
Ksenia S. Kirilovskaya — clinical resident of the Department of General Medical Practice of the Institute of Clinical Medicine named after. N.V. Sklifosovsky
Moscow
References
1. Turner J.P., Thompson W., Reeve E., Bell J.S. Deprescribing proton pump inhibitors. Aust. J. Gen. Pract. 2022;51(11):845–848. DOI: 10.31128/AJGP-07-22-649
2. Strand D.S., Kim D., Peura D.F. 25 years of proton pump inhibitors: A comprehensive review. Gut Liver. 2017;11(1):27–37. DOI: 10.5009/gnl15
3. Fujimori S. What are the effects of proton pump inhibitors on the small intestine? World J. Gastroenterol. 2015;21(22):6817–6819. DOI: 10.3748/wjg.v21.i22.6817
4. Kiecka A., Szczanik M. Proton pump inhibitor-induced gut dysbiosis and immunomodulation: current knowledge and potential restoration by probiotics. Pharmacol. Rep. 2023 ;75(4):791–804. DOI: 10.1007/s43440-023-00489-x
5. McDonald E.G., Milligan J., Frenette C., Lee T.C. Continuous proton pump inhibitor therapy and the associated risk of recurrent Clostridium difficile infection. JAMA Intern. Med. 2015;175(5):784–791. DOI: 10.1001/jamainternmed.2015.4
6. Kwok C.S., Arthur A.S., Anibueze C.I., Sungh S., Cavalkazzi R., Loke Y.K. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am. J. Gastroenterol. 2012;107(7):1011–1019. DOI: 10.1038/ajg.2012.108
7. Tawam D., Baladi M., Jungsuwadee P., Earl G., Han J. The рositive association between proton pump inhibitors and Clostridium difficile infection. Innov. Pharm. 2021;12(1):10.24926/iip.v12i1.3439. DOI: 10.24926/iip.v12i1.3439
8. Haastrup P.F., Thompson W., Sondergaard J., Jarbol D.E. Side effects of long-term proton pump inhibitor use: A review. Basic Clin. Pharmacol. Toxicol. 2018;123(2):114–121. DOI: 10.1111/bcpt.13023
9. Fatima K., Almas T., Lakhani S. Jahangir A., Ahmed A. Siddiqui A. et al. The use of proton pump inhibitors and COVID-19: A systematic review and meta-analysis. Trop. Med. Infect Dis. 2022;7(3):37. DOI: 10.3390/tropicalmed7030037
10. Lundell L., Vieth M., Gibson F., Nagy P., Kahrilas P.J. Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. Alliment. Pharmacol. Ther. 2015;42(6):649–663. DOI: 10.1111/apt.13324
11. Ahn J.S., Eom C.-S., Jeon C.S., Park S.M. Acid suppressive drugs and gastric cancer: a meta-analysis of observational studies. World J. Gastroenterol. 2013;19(16):2560–2568. DOI: 10.3748/wjg.v19.i16.2560
12. Guo H., Zhang R., Zhang P. Chen Z., Hua Y., Huang X., Li X. Association of proton pump inhibitors with gastric and colorectal cancer risk: A systematic review and meta-analysis. Front. Pharmacol. 2023;14:1129948. DOI: 10.3389/fphar.2023.1129948
13. Gao H., Li L., Geng K., Teng C., Chen Y., Chu F., Zhao Y. Use of proton pump inhibitors for the risk of gastric cancer. Medicine (Baltimore). 2022;101(49):e32228. DOI: 10.1097/MD.0000000000032228
14. Brusselaers N., Wahlin K., Engstrand L., Lagergren J. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden. BMJ Open. 2017;7(10):e017739. DOI: 10.1136/bmjopen-2017-017739
15. Crafa P., Franceschi M., Rodrigues-Castro K.I., Franzoni L., Russo M., Brandimarte G. et al. PPIs and gastric cancer: any causal relationship? Biomed. 2023;94(3):e2023096. DOI: 10.23750/abm.v94i3.14105
16. Shih C.-J., Chen Y.-T., Ou S.-Y., Li S,-Y., Chen T.-J., Wang S.-J. Proton pump inhibitor use represents an independent risk factor for myocardial infarction. Int. J. Cardiol. 2014;177(1):292–297. DOI: 10.1016/j.ijcard.2014.09.036
17. Ariel H., Cooke J.P. Cardiovascular risk of proton pump inhibitors. Methodist Debakey Cardiovasc. J. 2019;15(3):214–219. DOI: 10.14797/mdcj-15-3-21418
18. Lee D., Kim J.S., Kim B.J., Shin S.Y., Kim D.B., Ahn H.S. Influence of individual proton pump inhibitors on clinical outcomes in patients receiving clopidogrel following percutaneous coronary intervention. Medicine (Baltimore). 2021;100(52):e27411. DOI: 10.1097/MD.0000000000027411
19. Han Y.-Y., Li Z.-X., Duan R. Efficacy and safety of proton pump inhibitors combined with clopidogrel in patients undergoing percutaneous coronary intervention: a meta-analysis. Rev. Cardiovasc. Med. 2021;22(1):167–174. DOI: 10.31083/j.rcm.2021.01.296
20. Shi D., Zhou Z., Dai Y., Pan X., Cao Q. Proton pump inhibitor therapy and hepatic encephalopathy risk in cirrhotic patients: A systematic review with meta-analysis. Clin. Drug Investig. 2019;39(9):847–856. DOI:10.1007/s40261-019-00810-8
21. Kuan Y.-C., Huang K.-W., Lin C.-L., Luo J.-C., Kao C.-H. Short-term proton pump inhibitor use and hepatic encephalopathy risk in patients with decompensated cirrhosis. J. Clin. Med. 2019;8(8):1108. DOI: 10.3390/jcm8081108
22. Nochaiwong S., Ruengorn C., Awiphan R., Koyratkoson K., Chasai C., Noppakun K. et al. The association between proton pump inhibitor use and the risk of adverse kidney outcomes: a systematic review and meta-analysis. Nephrol. Dial. Transplant. 2018;33(2):331–342. DOI: 10.1093/ndt/gfw470
23. Hart E., Dunn T.E., Feuerstein S., Jacobs D.M. Proton pump inhibitors and risk of acute and chronic kidney disease: A retrospective cohort study. Pharmacotherapy. 2019;39(4):443–453. DOI: 10.1002/phar.2235
24. Morschel C.F., Mafra D., Carraro Eduardo J.C. The relationship between proton pump inhibitors and renal disease. J. Bras. Nefrol. 2018;40(3):301–306. DOI: 10.1590/2175-8239-jbn-2018-0021
25. Schiffl H., Al-Nemnem Е., Lang S.M. Proton-pump inhibitors and chronic kidney disease: Hidden consequences of an inappropriate drug use? Saudi J. Kidney Dis. Transpl. 2020;31(2):312–319. DOI: 10.4103/1319-2442.284005
26. Guedes J.V.M., Aquino J.A., Castro T.L.B., de Morais F.A., Baldoni A.O., Belo V.S., Otoni A. Omeprazole use and risk of chronic kidney disease evolution. PLoS One. 2020;15(3):e0229344 DOI: 10.1371/journal.pone.0229344
27. Kamal F., Khan M.A., Molnar M.Z., Howden C.W. The association between proton pump inhibitor use with acute kidney injury and chronic kidney disease. J. Clin. Gastroenterol. 2018;52(6):468–476. DOI: 10.1097/MCG.000000000000103528
28. Cheema E. Investigating the association of proton pump inhibitors with chronic kidney disease and its impact on clinical practice and future research: a review. J. Pharm. Policy Pract. 2019;12:6. DOI: 10.1186/s40545-019-0167-0
29. Gommers L.M.M., Hoenderop J.G., de Baaij J.H.F. Mechanisms of proton pump inhibitor-induced hypomagnesemia. Acta Physiol. (Oxf). 2022;235(4):e13846. DOI: 10.1111/apha.13846
30. Lam J.R., Schneider J.L., Zhao W., Corley D.A. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B 12 deficiency. JAMA. 2013;310(22):2435–2442. DOI: 10.1001/jama.2013.280490
31. Swarnakari K.M., Bai M., Manoharan M.P., Raja R., Jamil A., Csendes D. et al. The effects of proton pump inhibitors in acid hypersecretion-induced vitamin B 12 defi ciency: A systematic review (2022). Cureus. 2022;14(11):e31672. DOI: 10.7759/cureus.31672
32. den Elzen W.P.J., Groeneveld Y., de Ruijter W., Souverijn J.H.M., le Cessie S., Assendelft J., Gussekloo J. Long-term use of proton pump inhibitors and vitamin B 12 status in elderly individuals. Aliment. Pharmacol. Ther. 2008;27(6):491–497. DOI: 10.1111/j.1365-2036.2008.03601.x
33. Brigant S.J., Naciu A.V., Tabacco G., Cesareo R., Napoli N. Trimboli P. et al. Proton pump inhibitors and fractures in adults: A critical appraisal and review of the literature. J. Endocrinol. 2021;2021:8902367. DOI: 10.1155/2021/8902367
34. Li M., Luo Z., Yu S., Tang Z. Proton pump inhibitor use and risk of dementia: Systematic review and meta-analysis. Medicine (Baltimore). 201998(7):e14422. DOI: 10.1097/MD.0000000000014422
35. Vaezy M.F., Yang Y.-X., Howden C.W. Complications of proton pump inhibitor therapy. Gastroenterology. 2017;153(1):35–48. DOI: 10.1053/j.gastro.2017.04.047
Review
For citations:
Sheptulin A.A., Kirilovsky A.A., Kirilovskaya K.S. Side effects of proton pump inhibitors: how real are they in clinical practice? Clinical Medicine (Russian Journal). 2024;102(1):57-61. (In Russ.) https://doi.org/10.30629/0023-2149-2024-102-1-57-61
Views:
370
Email this article 